This document is the package insert for Invega Trinza, a 3-month injectable antipsychotic medication used for schizophrenia, detailing dosage…
This document serves as the official package insert for Invega Trinza (Paliperidone Palmitate Injection), a long-acting injectable antipsychotic medication. It provides comprehensive instructions for medical professionals regarding the drug's usage, including specific dosing schedules for patients transitioning from monthly injections or oral medications.
The text details the administration procedures, such as the requirement for intramuscular injection into the deltoid or gluteal muscle, the specific needle sizes based on patient weight, and the necessity of vigorous shaking before injection. It also outlines protocols for missed doses and dose adjustments for patients with renal impairment. This manual is written in Chinese.
| Indication | Schizophrenia in patients who have received at least 4 months of adequate treatment with Invega Sustenna |
|---|---|
| Dosage Interval | Every 3 months |
| Route of Administration | Intramuscular injection only |
| Active Ingredient | Paliperidone Palmitate |
| Available Strengths | 175 mg, 263 mg, 350 mg, 525 mg |
The medication should be administered once every 3 months.
A 1-inch 22-gauge thin-wall needle is recommended for patients weighing less than 90 kg.
No, the drug is not approved for this use and may increase mortality in elderly patients with dementia-related psychosis.
If the time since the last injection is between 3.5 and 4 months, administer the previous dose immediately. If it is 4 to 9 months, a restart protocol is required.